Found: IMH0030 - Men's health Prostate Cancer Research Written Evidence

Found: in public awareness and social media coverage with well-known celebrities and campaigning by PCUK, Prostate

Found: , 2023 iv Men’s Health Forum, Men and cancer: saving lives, 2013 v Prostate Cancer Research, New

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, how much funding her Department has allocated to prostate cancer research in the last 5 years.

Answered by Andrew Stephenson

The Department is proud to invest £1.3 billion per year in health research through the National Institute for Health and Care Research (NIHR). NIHR research expenditure for all cancers was over £121.8 million for 2022/23, with more spent on cancer than any other disease group. In 2018, the Government announced £75 million towards clinical trials for prostate cancer, with a focus on improving early diagnosis, survival rates, and exploring options for different treatments for men affected by the disease.

Since April 2019, the NIHR has awarded £79.1 million across 49 prostate cancer research programmes. Research includes randomised controlled trials of different treatments for prostate cancer, a randomised controlled trial of different methods of biopsy for suspected prostate cancer, and survivors' rehabilitation evaluation after cancer.

On 19 November 2023, the Government and Prostate Cancer UK announced a £42 million screening trial to find ways of detecting the country’s most common male cancer earlier. Prostate Cancer UK is leading the development of the trial, with the Government contributing £16 million through the Department. Additionally, the NIHR supported over 100 commercial and non-commercial clinical research studies in 2023/24, through the NIHR Research Delivery Network.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the press notice entitled Biggest prostate cancer screening trial in decades to start in UK published on 19 November 2023, what assessment her Department has made of the additional workforce capacity that will be required to deliver the trial.

Answered by Andrew Stephenson

The Department funds research through the National Institute for Health and Care Research (NIHR). NIHR invests in the research delivery workforce, the facilities and capacity to support clinical trials. The NIHR Clinical Research Facilities and Experimental Cancer Medicine Centres support the delivery of early phase trials and the NIHR Clinical Research Network and Patient Recruitment Centres support delivery and participation in later phase clinical trials. The prostate cancer trial announced on 19 November will be run by Prostate Cancer UK with the Government contributing alongside others.

To maximise research participation, the NIHR provides the online platform ‘Be Part of Research’, which allows users to search for and register their interest in participating in the clinical trials of most interest and relevance to them. NIHR has also supported initiatives to increase diagnosis rates and participation in prostate cancer research by men from black and minority ethnic groups.

The recently announced TRANSFORM trial aims to save thousands of men each year by finding the best way to screen for prostate cancer. The trial will be United Kingdom-wide, although final decisions on specific locations are yet to be taken. Men will be invited to participate via their general practices. This study will also aim to address some of the inequalities that exist in prostate cancer diagnosis today by ensuring that one in 10 of the trial participants will be black men, who are three times overrepresented compared to the population of men aged 45 to 75 as based on 2021 census data.

The UK National Screening Committee will be reviewing the evidence that is published by this study. This will help to inform any future recommendation on creating a national screening programme for prostate cancer.

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the press notice entitled Biggest prostate cancer screening trial in decades to start in UK published on 19 November 2023, in which areas will the trial be carried out; and what steps her Department is taking to (a) ensure there is sufficient diagnostics capacity to deliver the additional screening in the trial areas in local areas to deliver increased screening and (b) encourage participation amongst (i) at-risk groups and (ii) black men.

Answered by Andrew Stephenson

The Department funds research through the National Institute for Health and Care Research (NIHR). NIHR invests in the research delivery workforce, the facilities and capacity to support clinical trials. The NIHR Clinical Research Facilities and Experimental Cancer Medicine Centres support the delivery of early phase trials and the NIHR Clinical Research Network and Patient Recruitment Centres support delivery and participation in later phase clinical trials. The prostate cancer trial announced on 19 November will be run by Prostate Cancer UK with the Government contributing alongside others.

To maximise research participation, the NIHR provides the online platform ‘Be Part of Research’, which allows users to search for and register their interest in participating in the clinical trials of most interest and relevance to them. NIHR has also supported initiatives to increase diagnosis rates and participation in prostate cancer research by men from black and minority ethnic groups.

The recently announced TRANSFORM trial aims to save thousands of men each year by finding the best way to screen for prostate cancer. The trial will be United Kingdom-wide, although final decisions on specific locations are yet to be taken. Men will be invited to participate via their general practices. This study will also aim to address some of the inequalities that exist in prostate cancer diagnosis today by ensuring that one in 10 of the trial participants will be black men, who are three times overrepresented compared to the population of men aged 45 to 75 as based on 2021 census data.

The UK National Screening Committee will be reviewing the evidence that is published by this study. This will help to inform any future recommendation on creating a national screening programme for prostate cancer.

Found: Prostate Cancer Research 183. Public Policy Projects 184.

Found: Jeremy Hunt 17/10/2023 Soho House; Prostate Cancer Research To discuss the Daily Mail campaign ‘End Needless

Found: Interest is non - specific Rakesh Heer Chair Indirect financial Principle Investigator, Prostate

Found: Interest is non - specific Rakesh Heer Chair Indirect financial Principle Investigator, Prostate

Found: Orchid • PCaSO - Prostate Cancer Support Organisation • Pelican Cancer Foundation • Prost8 UK • Prostate

Found: Interest is non - specific Rakesh Heer Chair Indirect financial Principle Investigator, Prostate

Found: Orchid • PCaSO - Prostate Cancer Support Organisation • Pelican Cancer Foundation • Prost8 UK • Prostate

Found: measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials --does HRQOL evaluation in prostate

Found: of strengthening patient insights and responding to requests for information: Prostate Cancer UK, Prostate

Found: of strengthening patient insights and responding to requests for information: Prostate Cancer UK, Prostate